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INTRODUCTION
Mucormycosis manifests in a variety of different clinical 
presentations in humans, particularly in immunocompro-
mised patients and those with diabetes mellitus.1 The agents 
of mucormycosis are common in the environment and can 
be found on decaying vegetation and in the soil.2 All humans 
have ample exposure to these fungi during day-to-day ac-
tivities. The fact that mucormycosis is a rare human infec-
tion reflects the effectiveness of the intact human immune 
system. This is supported by the finding that almost all hu-
man infections, due to the agents of mucormycosis, occur in 
the presence of some underlying compromising condition. 
We report a case of devastating rhino-orbital mucor-
mycosis in a patient with uncontrolled diabetes result-
ing in exenteration of the left eye. Prognosis is poor for 
patients with brain, cavernous sinus, or carotid involve-
ment.3-5 Hence, it is important to make an early diagnosis 
and initiate appropriate treatment, along with strict glyce-
mic control in diabetics, to decrease morbidity and mortality.
CASE REPORT
A 67-year-old male with stage IV chronic kidney disease, 
sleep apnea, coronary artery disease status post coronary artery 
bypass graft, and uncontrolled diabetes mellitus presented to an 
outside hospital with headache, nasal congestion, diplopia, and 
photophobia. The patient had invasive fungal sinusitis and un-
derwent endoscopic sinus surgery and debridement. Cultures 
grew Rhizopus. The patient was transferred to our hospital after 
he became blind in the left eye (reportedly the night prior to 
transfer) for further aggressive management with endoscopic 
sinus surgery for debridement of invasive fungal sinusitis.
On exam, the patient had proptosis of the left eye. He had left 
afferent pupillary defect, severely restricted gaze, and decreased 
sensation in all branches of the trigeminal nerve. Labs were signif-
icant for hemoglobin of 9.2 g/dl, a white blood count of 13.5 K/µl, 
BUN of 62 mg/dl, creatinine of 2.05 mg/dl, and glucose of 323 mg/dl. 
Maxillofacial computed tomography (CT) showed inter-
val left maxillary antrectomy with improvement in max-
illary sinusitis, progression in left ethmoid, frontal and 
bilateral sphenoid sinusitis, and development of post-
septal fat stranding with asymmetric prominence of op-
tic nerve consistent with orbital (post-septal) cellulitis. 
Ophthalmology was consulted and the patient underwent left 
medial orbital exploration and radical orbital exenteration. Pa-
thology showed involvement of middle turbinate, inferior orbital 
nerve, orbital floor bone, and orbital contents with fungal organ-
isms with vascular invasion consistent with Mucor (Figure 1).
Figure 1. Left orbit enucleation specimen showing fungal organisms 
with vascular invasion consistent with Mucor. 
The patient was started on piperacillin and tazobactam, mi-
cafungin sodium, and amphotericin B; oral posaconazole was 
added later. Strict glycemic control was targeted and achieved 
throughout the hospital course. Piperacillin and tazobactam 
was discontinued on discharge. The patient was discharged to 
a skilled nursing facility [SNF] and advised to continue IV am-
photericin and micafungin sodium, to complete a total of four 
weeks, and oral posaconazole indefinitely. He did well while he 
was on IV antifungals; once the duration of IV antifungals ended, 
he rapidly deteriorated and eventually passed away at the SNF.
DISCUSSION 
Mucormycosis can manifest as devastating rhino-orbital-
cerebral (ROC) and pulmonary infections in immunocompro-
mised patients and in diabetics.1 The genera common in hu-
mans are Rhizopus, Mucor, and Rhizomucor. The hyphae are 
broad, irregularly branched, and have rare septations. Rhizopus 
organisms have an enzyme, ketone reductase, which allows 
them to thrive in high glucose, acidic conditions. ROC and pul-
monary mucormycosis are acquired by inhalation of spores. 
Infection usually begins in the nasal turbinates or alveoli.6
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The agents of mucormycosis are angioinvasive; infarction of 
infected tissues is a hallmark of invasive disease.7 Predisposing 
conditions are diabetes mellitus, particularly with diabetic keto-
acidosis, glucocorticoid use, hematologic malignancies, hema-
topoietic stem cell/solid organ transplantation, deferoxamine, 
iron overload, AIDS, IV drug use, trauma/burns and malnutri-
tion. ROC mucormycosis presents with fever, nasal ulceration/
necrosis, periorbital/facial swelling, decreased vision, ophthal-
moplegia, sinusitis, and headache. Signs of orbital involvement 
are periorbital edema, proptosis, and blindness. Facial numb-
ness results from infarction of sensory branches of trigeminal 
nerve. The spread of infection from the ethmoid sinus to the 
frontal lobe results in obtundation. Spread from the sphenoid 
sinuses to cavernous sinus can result in cranial nerve palsies, 
thrombosis of the sinus, and involvement of carotid artery. 
ROC mucormycosis should be suspected in patients with 
diabetes mellitus and metabolic acidosis who present with si-
nusitis, altered mentation, and infarcted tissue in the nose/
palate.2 The diagnosis of mucormycosis relies upon the iden-
tification of organisms in tissue by histopathology with cul-
ture confirmation. However, culture often yields no growth 
and histopathologic identification of an organism with a 
structure typical of Mucorales may provide the only evi-
dence of infection. A clinician must think of this entity in the 
appropriate clinical setting and pursue invasive testing to es-
tablish a diagnosis as early as possible. The presence of the 
characteristic hyphae in a clinical specimen provides a pre-
sumptive diagnosis that should prompt further evaluation.
Further evaluation includes imaging of the head with ei-
ther CT or magnetic resonance imaging (MRI) to look for si-
nus involvement and evaluate contiguous structures, such 
as the eyes and brain.8 Treatment of mucormycosis includes 
surgical debridement and antifungal therapy.9 IV ampho-
tericin B is the drug of choice for initial therapy.10 Lipid 
formulation of amphotericin B is preferred over ampho-
tericin B deoxycholate to deliver a high dose with less neph-
rotoxicity. The usual duration of treatment with IV ampho-
tericin B is several weeks, until a favorable clinical response 
is achieved and at that point can be switched to posaconazole.
Posaconazole is used as step-down therapy for patients who 
have responded to amphotericin B. Posaconazole also can be 
used as salvage therapy for patients who do not respond or 
cannot tolerate amphotericin B. For salvage therapy, the deci-
sion to use oral or intravenous posaconazole depends on how 
ill the patient is, whether an initial course of amphotericin B 
was administered, and whether the patient had a functioning 
gastrointestinal tract. When switching to oral posaconazole, 
delayed-release formulation (300 mg every 12 hours on the 
first day, then 300 mg once daily) is favored.11 Therapy with 
posaconazole should continue until there is clinical resolution 
of the signs and symptoms of infection, as well as resolution of 
radiographic signs of active disease which often takes months. 
Isavuconazole, available in both an IV and an oral formula-
tion, can be used if the patient cannot tolerate posaconazole.
Echinocandins [Micafungin] have no in vitro activ-
ity against the agents of mucormycosis,12-14 but Rhi-
zopus oryzae, the most common cause of mucormy-
cosis, expresses the target enzyme for echinocandins, 
suggesting that these agents may have clinical utility.15
Mortality from ROC mucormycosis ranges from 25% to 62%.16 
Factors associated with death are delayed diagnosis, presence 
of hemiparesis/hemiplegia, bilateral sinus involvement, leuke-
mia, renal disease, and deferoxamine use.17 Prognosis is poor 
for patients with brain, cavernous sinus, or carotid involvement.
CONCLUSION
ROC mucormycosis is an invasive dis-
ease with high mortality. Despite early 
diagnosis and aggressive combined surgi-
cal and medical therapy, the prognosis for recovery
from mucormycosis is poor. Bilateral sinus in-
volvement is one of the poor prognostic indicators. 
Our patient had bilateral sphenoid sinus involvement. Hence, 
being cognizant of the clinical manifestations and presentation is 
important for an early diagnosis and initiating appropriate treat-
ment at the earliest is crucial to decrease morbidity and mortality.
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